Results 11 to 20 of about 55,779 (204)
Development of peptide vaccines in dengue [PDF]
Current Pharmaceutical Design, 2017 Dengue is one of the most important arboviral infection worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people ...
Chan, Yanqi +3 more
core +4 more sources
Controlling dengue with vaccines in Thailand.
PLoS Neglected Tropical Diseases, 2012 BackgroundDengue is a mosquito-borne infectious disease that constitutes a growing global threat with the habitat expansion of its vectors Aedes aegyti and A. albopictus and increasing urbanization.
Dennis L Chao +3 more
doaj +3 more sources
BioDrugs, 2022 Dengue is one of the most prevalent mosquito-borne diseases in the world, affecting an estimated 390 million people each year, according to models. For the last two decades, efforts to develop safe and effective vaccines to prevent dengue virus (DENV) infections have faced several challenges, mostly related to the complexity of conducting long-term ...
Jesús M. Torres-Flores +2 more
openaire +2 more sources
Archives of the Balkan Medical Union, 2022 Dengue is estimated to be the most common mosquito-borne disease globally, affecting mainly tropical and subtropical countries. It has been identified as a disease of the future, due to persistent trends in urbanization of societies, scarce water resources and changes in the environment. The four dengue virus serotypes cause from the usual mild illness
Radka KOMITOV +3 more
openaire +2 more sources
BMC Public Health, 2022 Background Dengue vaccine is a promising alternative for protecting communities from dengue. Nevertheless, public acceptance of the dengue vaccine must be considered before the authorities decide to carry out intensified research and recommend the ...
Ahmad Firdhaus Arham +6 more
doaj +1 more source
Vaccines, 2022 Infection with viruses belonging to the genus Flavivirus, such as Japanese encephalitis virus (JEV) and dengue virus (DENV), is a worldwide health problem. Vaccines against JEV and DENV are currently available.
Tomohiro Kotaki +4 more
doaj +1 more source
Pathogenesis of Dengue: Dawn of a New Era [version 1; referees: 3 approved]
F1000Research, 2015 Dengue virus (DENV) infections of humans were long thought to be self-limited and of low mortality. Beginning in the 1950s, at the time when four different DENVs were discovered, a lethal variant of dengue emerged.
Scott B. Halstead
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2021 In 2019, Bangladesh has grappled with a record-breaking surge in dengue fever, experiencing the highest number of dengue cases since the year 2000. Together, the intensification of dengue fever combined with a lack of dengue vaccines and appropriate ...
K M Ariful Kabir +2 more
doaj +1 more source
Dengue Vaccine, Challenges, Development and Strategies [PDF]
, 2014 Dengue fever is endemic in more than 100 countries in the world. The effective dengue antiviral drug has not been found yet,and vector control is considered less effective. Prevention program by vaccination is needed.
Marbawati, D. (Dewi) +1 more
core +2 more sources
Key Amino Acid Substitution for Infection-Enhancing Activity-Free Designer Dengue Vaccines
iScience, 2019 Summary: Dengue is a globally important disease caused by four serotypes of dengue virus. Dengue vaccine development has been hampered by antigenic cross-reactivity among serotypes, which potentially causes antibody-dependent enhancement of infection and
Atsushi Yamanaka, Eiji Konishi
doaj +1 more source